AIDS Research and Therapy is a prestigious peer-reviewed journal dedicated to disseminating cutting-edge research in the fields of AIDS and HIV therapy. Published by BMC, this Open Access journal has been freely available since its inception in 2004, facilitating global access to vital research findings. Based in the United Kingdom, the journal covers a diverse range of topics including molecular medicine, pharmacology, and virology, making it a crucial resource for researchers and clinicians alike. Recognized for its strong impact within the scientific community, it holds a Q2 quartile ranking in multiple categories as of 2023, including Molecular Medicine and Pharmacology. With an aim to enhance understanding and improve clinical outcomes for those affected by HIV/AIDS, AIDS Research and Therapy serves as an essential platform for the exchange of innovative ideas and practices that can inform future therapies and interventions. Researchers, professionals, and students seeking high-quality, peer-reviewed content will find this journal invaluable in advancing their knowledge and efforts in combating the HIV/AIDS epidemic.

Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.

The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.

Current HIV/AIDS Reports, published by Springer, is a distinguished scholarly journal that addresses critical developments in the field of HIV/AIDS research. As a leading publication within the Q1 quartiles for both Infectious Diseases and Virology, it serves as an essential platform for researchers and healthcare providers aiming to advance knowledge and practices related to HIV prevention, treatment, and care. With a commitment to publishing innovative studies, reviews, and clinical guidelines, this journal fosters a comprehensive understanding of the complexities surrounding HIV/AIDS. The journal enjoys a robust reputation, evidenced by its impressive Scopus rankings, including a rank of #69 in Infectious Diseases and #21 in Virology, placing it in the top echelons of its field. With an open-access model, *Current HIV/AIDS Reports* significantly enhances the accessibility of crucial research findings to a global audience, driving progress in HIV/AIDS knowledge and public health.

The Indian Journal of Sexually Transmitted Diseases and AIDS, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, serves as a vital platform for disseminating research and knowledge in the fields of sexually transmitted infections and HIV/AIDS management. With ISSN 2589-0557 and E-ISSN 2589-0565, this journal aims to bridge the gap in public health and clinical research by providing peer-reviewed articles that cover a range of topics from epidemiology to therapeutic advancements. Despite its status with an impact factor in the lower quartiles across relevant categories, including Q3 in Dermatology, Q4 in Infectious Diseases, and Q4 in Public Health, it holds potential for growth and greater visibility within the academic community. The journal's scope spans critical insights and innovative approaches in managing sexually transmitted diseases, and it is committed to fostering scholarly discourse among its readership consisting of researchers, health professionals, and students alike. As it converges from 2018 to 2024, the Indian Journal of Sexually Transmitted Diseases and AIDS continues to underscore the importance of addressing pressing health issues in India and beyond, while offering an accessible resource for those dedicated to this vital field.

Retrovirology is a prominent open-access journal published by BMC since 2004, dedicated to the field of retroviral research. With a strong focus on advancing knowledge in both infectious diseases and virology, this interdisciplinary journal has achieved a commendable ranking of Q2 in its respective categories as of 2023, reflecting its significant contribution to the scientific community. Hosted in the United Kingdom, Retrovirology serves a global audience of researchers, professionals, and students, making vital research accessible to all without barriers. The journal's emphasis on high-quality peer-reviewed articles supports the dissemination of groundbreaking findings that could shape the future of virology and related fields. With an impressive Scopus ranking, including a percentile of 65th in Medicine: Infectious Diseases, it stands out as a valuable resource for those committed to understanding and combating viral diseases. Retrovirology continues to be an essential platform for innovative research, with its open-access model ensuring that transformational science reaches the widest possible audience.

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

HIV Research & Clinical Practice, published by Taylor & Francis Ltd, is an essential open-access journal dedicated to advancing the knowledge and understanding of HIV-related research and clinical practices. With an ISSN of 2578-7489 and E-ISSN 2578-7470, this acclaimed journal is committed to disseminating cutting-edge studies and innovative treatment strategies within the infectious diseases and pharmacology fields, achieving a commendable Q2 ranking in both categories as of 2023. The journal's scope encompasses a broad range of topics from basic science to clinical application, providing a vital platform for researchers, clinicians, and students to exchange insights and foster collaboration. As an open-access publication since 2022, it ensures that high-quality research is accessible to a global audience, encouraging a greater understanding of HIV and its implications for public health. With its base in the United Kingdom and a convergence period from 2019 to 2024, HIV Research & Clinical Practice stands at the forefront of the fight against HIV/AIDS, making significant contributions to the clinical community and beyond.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

Current Opinion in HIV and AIDS is a pivotal journal published by Lippincott Williams & Wilkins, dedicated to the dissemination of cutting-edge research and insights in the rapidly evolving fields of HIV and AIDS. Established in 2007 and maintaining a comprehensive focus through to 2024, this journal has achieved an impressive position within academia, earning a Q1 ranking in multiple categories, including Hematology, Immunology, Infectious Diseases, Oncology, and Virology as of 2023, indicative of its high impact and relevance. Researchers and professionals benefit from its curated reviews that synthesize current knowledge, highlight emerging trends, and address clinical applications. While the journal is not open access, it remains a vital resource housed in prestigious databases, ensuring that vital information reaches a broad audience. The ISSN for print is 1746-630X and its E-ISSN is 1746-6318. Located in Philadelphia, PA, the journal's commitment to innovation and education makes it an essential platform for those engaged in combating one of the most pressing health challenges of our time.